GlycoVaxyn Trialing New Vaccine Technology For Recurrent UTIs, Shigella
This article was originally published in The Pink Sheet Daily
Executive Summary
A new method of making vaccines, called bio-conjugation, may be more efficient and cost effective than chemical conjugation methods used by Pfizer for Prevnar and other vaccine makers, and it may address new pathogens too.